Trial · NCT07908433
Study of the Safety and Efficacy of Prenofitol Tablets
NCT07908433, Phase 2, Not yet recruiting, Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of the Safety and Efficacy of Prenofitol Tablets. Trials, record NCT07908433. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908433
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of the Safety and Efficacy of Prenofitol Tablets
- NCT number
- NCT07908433
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 160 participants, estimated
- Lead sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Conditions
- Dyslipidemia
- Interventions
- 1 tablet of Prenofitol, 2 tablets of Prenofitol, 1 tablet of placebo, 2 tablets of placebo
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of patients achieving the target LDL-C level of <3.0 mmol/L compared with the baseline value in the investigational treatment groups and the placebo group at 90 days from the start of treatment (Visit 8). | 180 days from the start of treatment | |
| Secondary | The proportion of patients achieving a ≥50% reduction in LDL-C from the baseline value in the investigational treatment groups and the placebo group at 90 days from the start of treatment (Visit 8) | 180 days from the start of treatment | |
| Secondary | The proportion of patients achieving a ≥25% reduction in LDL-C from the baseline value in the investigational treatment groups and the placebo group at 90 days from the start of treatment (Visit 8) | 180 days from the start of treatment | |
| Secondary | The proportion of patients achieving an LDL-C level of <3.0 mmol/L compared with the baseline value in the investigational treatment groups and the placebo group | 180 days from the start of treatment | |
| Secondary | The change in lipid metabolism parameters, including triglyceride levels, in the investigational treatment groups and the placebo group | 180 days from the start of treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908433
GET https://conductscience.org/api/trials/v1/NCT07908433/registered